Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

Overview of attention for article published in Journal of Clinical Oncology, February 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

news: 2 news outlets

guideline: 1 clinical guideline source

Readers on

mendeley: 41 Mendeley

So far, Altmetric has seen 5 news stories from 2 outlets.

Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits Responses in Advanced Urothelial Cancer

OncLive, 26 Jul 2022

Enfortumab vedotin-ejfv plus pembrolizumab induced encouraging responses when used in the frontline treatment of patients with…

Treatment Strategies in Metastatic Urothelial Carcinoma With Immune Checkpoint Inhibitors and Targeted Therapies

Cancer Network, 14 Mar 2022

Daniel P. Petrylak, MD, reviews the current systemic therapy treatment paradigm in metastatic urothelial carcinoma.

Nectin-4 Emerges as a Therapeutic Target in Urothelial Carcinoma and Beyond

OncLive, 02 Jan 2022

Most ongoing clinical trials exploring nectin-4 as a target involve studies of enfortumab vedotin and its potential synergy…

Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook

Cancer Network, 15 Jul 2021

Until 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.